A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
About the study
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Key Inclusion Criteria:
- Clinical history of T1D with greater than or equal to (>=) 5 years duration
- Participant is on a stable diabetic treatment
- Consistent use of continuous glucose monitoring (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study
EXCLUSION CRITERIA
Key Exclusion Criteria:
* Prior islet cell transplant, organ transplant, or cell therapy
Other protocol defined Inclusion/Exclusion criteria may apply.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Type 1 Diabetes
Age
18+
Phase
PHASE1/PHASE2
Participants Needed
17
Est. Completion Date
May 31, 2026
Treatment Type
INTERVENTIONAL
Sponsor
Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov NCT Identifier
NCT05791201
Study Number
VX22-264-101
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?